Wang L H, Lee C S, Marbury T C
Am J Hosp Pharm. 1980 Jul;37(7):956-8.
The effect of hemodialysis on plasma mefenamic acid levels was studied in four patients on long-term hemodialysis. A 500-mg oral dose of mefenamic acid was administered to the fasting patients two hours before hemodialysis. Arterial and venous blood samples taken before dialysis, at 30-minute intervals during a three-hour dialysis, and immediately before termination of dialysis were assayed by high-performance liquid chromatography. Mefenamic acid half-life on hemodialysis was not reduced substantially compared with that reported for normal patients. The extraction efficiency of the hollow-fiber kidneys averaged 6.4%. The mean drug recovery was 1.03 mg or 0.2% of the administered dose. The extensive plasma protein binding (range: 85-97%) accounted for the poor recovery. The study suggests that adjustment of mefenamic acid dosage is not necessary in patients undergoing hemodialysis and that hemodialysis is of minimal value in the management of mefenamate overdose.
在4例长期接受血液透析的患者中研究了血液透析对血浆甲芬那酸水平的影响。在血液透析前两小时，给空腹患者口服500mg甲芬那酸。通过高效液相色谱法对透析前、三小时透析过程中每隔30分钟以及透析即将结束时采集的动脉和静脉血样进行分析。与正常患者报告的情况相比，血液透析中甲芬那酸的半衰期没有显著缩短。中空纤维肾的提取效率平均为6.4%。药物平均回收率为1.03mg，占给药剂量的0.2%。广泛的血浆蛋白结合（范围：85-97%）导致回收率较低。该研究表明，接受血液透析的患者无需调整甲芬那酸剂量，并且血液透析在甲芬那酸过量处理中的价值极小。
